Ultrapure water for HPLC analysis

June 5, 2019

This whitepaper demonstrates the High Performance Liquid Chromatography (HPLC) separation and analysis technique and highlights the importance of using water of sufficient purity as an eluent and how the arium® pro VF system can facilitate this.

Spotlight

OXiGENE, Inc.

OXiGENE is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that OXiGENE is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These 2 approaches (VDAs and AAs) have distinct yet complementary mechanisms of action.

OTHER WHITEPAPERS
news image

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Read More
news image

Biosimilars in the United States 2023–2027

whitePaper | January 31, 2023

The first biosimilar approved under the abbreviated pathway established by the Biologics Price Competition and Innovation Act launched in the U.S. in 2015.

Read More
news image

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More
news image

rFC adoption for bacterial endotoxin testing

whitePaper | December 7, 2022

OVER THE LAST 20 years, the worldwide value of traded pharmaceutical goods has grown six‑fold, from $113 billion in 2000 to $629 billion in 2019.1 Yet amid such robust growth comes risk to supply chain security as manufacturers become increasingly dependent on a global network of suppliers

Read More
news image

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic.

Read More
news image

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Read More

Spotlight

OXiGENE, Inc.

OXiGENE is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that OXiGENE is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These 2 approaches (VDAs and AAs) have distinct yet complementary mechanisms of action.

Events